1939

Large-scale trials in U.S. attest to effectiveness of the sulfonamides (esp. sulfapyridine) with pneumococcal pneumonia, leading to disuse of serum therapy for this condition: “Within a short time most doctors had abandoned the typing of pneumococci, pneumonia control programs had closed down, and pharmaceutical companies had stopped producing the serums because they were no longer profitable” (Dowling 1, 113-14).